Role of EGF inhibitors in the treatment of recurrent or metastatic squamous cell head and neck cancer

per Lorch, Jochen H
Publicat 2009

Exceptional Responders Inspire Change: Lessons for Drug Development From the Bedside to the Bench and Back

per Chau, Nicole G., Lorch, Jochen H.
Publicat a Oncologist (2015)

Induction Chemotherapy for Locoregionally Advanced Head and Neck Cancer: Past, Present, Future?

per Hanna, Glenn J., Haddad, Robert I., Lorch, Jochen H.
Publicat 2013

A case of primary secretory carcinoma of the thyroid with high-grade features

per Wu, Elizabeth Y, Lebastchi, Jasmin, Marqusee, Ellen, Lorch, Jochen H, Krane, Jeffrey F, Barletta, Justine A
Publicat a Histopathology (2017)

Genomic analysis of metastatic cutaneous squamous cell carcinoma

per Li, Yvonne Y., Hanna, Glenn J., Laga, Alvaro C., Haddad, Robert I., Lorch, Jochen H., Hammerman, Peter S.
Publicat a Clin Cancer Res (2015)

The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature

per Kumar, Vivek, Shinagare, Atul B., Rennke, Helmut G., Ghai, Sandeep, Lorch, Jochen H., Ott, Patrick A., Rahma, Osama E.
Publicat a Oncologist (2020)

Improved outcomes in PI3K-pathway-altered metastatic HPV oropharyngeal cancer

per Hanna, Glenn J., Kacew, Alec, Chau, Nicole G., Shivdasani, Priyanka, Lorch, Jochen H., Uppaluri, Ravindra, Haddad, Robert I., MacConaill, Laura E.
Publicat a JCI Insight (2018)

Long term results of TAX324, a randomized phase III trial of sequential therapy with TPF versus PF in locally advanced squamous cell cancer of the head and neck

per Lorch, Jochen H., Goloubeva, Olga, Haddad, Robert I., Cullen, Kevin, Sarlis, Nicholas, Tishler, Roy, Tan, Ming, Fasciano, John, Sammartino, Daniel E., Posner, Marshall R.
Publicat a Lancet Oncol (2011)

Trastuzumab for the Treatment of Salivary Duct Carcinoma

per Limaye, Sewanti A., Posner, Marshall R., Krane, Jeffrey F., Fonfria, Maria, Lorch, Jochen H., Dillon, Deborah A., Shreenivas, Aditya V., Tishler, Roy B., Haddad, Robert I.
Publicat 2013

Frameshift events predict anti–PD-1/L1 response in head and neck cancer

per Hanna, Glenn J., Lizotte, Patrick, Cavanaugh, Megan, Kuo, Frank C., Shivdasani, Priyanka, Frieden, Alexander, Chau, Nicole G., Schoenfeld, Jonathan D., Lorch, Jochen H., Uppaluri, Ravindra, MacConaill, Laura E., Haddad, Robert I.
Publicat a JCI Insight (2018)

Association of Programmed Death 1 Protein Ligand (PD-L1) Expression With Prognosis in Merkel Cell Carcinoma

per Hanna, Glenn J., Kacew, Alec J., Tanguturi, Anusha R., Grote, Hans J., Vergara, Victoria, Brunkhorst, Beatrice, Rabinowits, Guilherme, Thakuria, Manisha, LeBoeuf, Nicole R., Ihling, Christian, DeCaprio, James A., Lorch, Jochen H.
Publicat a Front Med (Lausanne) (2020)

The Benefits of Adjuvant Trastuzumab for HER‐2‐Positive Salivary Gland Cancers

per Hanna, Glenn J., Bae, Ji Eun, Lorch, Jochen H., Haddad, Robert I., Jo, Vickie Y., Schoenfeld, Jonathan D., Margalit, Danielle N., Tishler, Roy B., Goguen, Laura A., Annino, Donald J., Chau, Nicole G.
Publicat a Oncologist (2020)

Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer

per Sridharan, Vishwajith, Margalit, Danielle N, Lynch, Stephanie A, Severgnini, Mariano, Zhou, Jun, Chau, Nicole G, Rabinowits, Guilherme, Lorch, Jochen H, Hammerman, Peter S, Hodi, F Stephen, Haddad, Robert I, Tishler, Roy B, Schoenfeld, Jonathan D
Publicat a Br J Cancer (2016)

Hospitalization rates and 30-day all-cause mortality among head and neck cancer patients and survivors with COVID-19

per Hanna, Glenn J., Rettig, Eleni M., Park, Jong C., Varvares, Mark A., Lorch, Jochen H., Margalit, Danielle N., Schoenfeld, Jonathan D., Tishler, Roy B., Goguen, Laura A., Annino, Donald J., Haddad, Robert I., Uppaluri, Ravindra
Publicat a Oral Oncol (2021)

Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial

per Kaufman, Howard L., Russell, Jeffery S., Hamid, Omid, Bhatia, Shailender, Terheyden, Patrick, D’Angelo, Sandra P., Shih, Kent C., Lebbé, Céleste, Milella, Michele, Brownell, Isaac, Lewis, Karl D., Lorch, Jochen H., von Heydebreck, Anja, Hennessy, Meliessa, Nghiem, Paul
Publicat a J Immunother Cancer (2018)

Acupuncture for Chemoradiation Therapy-Related Dysphagia in Head and Neck Cancer: A Pilot Randomized Sham-Controlled Trial

per Lu, Weidong, Wayne, Peter M., Davis, Roger B., Buring, Julie E., Li, Hailun, Macklin, Eric A., Lorch, Jochen H., Burke, Elaine, Haddad, Tyler C., Goguen, Laura A., Rosenthal, David S., Tishler, Roy B., Posner, Marshall R., Haddad, Robert I.
Publicat a Oncologist (2016)

Human papillomavirus (HPV) 16 antibodies at diagnosis of HPV-related oropharyngeal cancer and antibody trajectories after treatment

per Zhang, Yuehan, Waterboer, Tim, Haddad, Robert I., Miles, Brett A., Wentz, Alicia, Gross, Neil D., Fakhry, Carole, Quon, Harry, Lorch, Jochen H., Gourin, Christine G., Clayburgh, Daniel, Misiukiewicz, Krzysztof J., Richmon, Jeremy D., Andersen, Peter E., Posner, Marshall R., D’Souza, Gypsyamber
Publicat a Oral Oncol (2017)

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

per Kaufman, Howard L, Russell, Jeffery, Hamid, Omid, Bhatia, Shailender, Terheyden, Patrick, D’Angelo, Sandra P, Shih, Kent C, Lebbé, Céleste, Linette, Gerald P, Milella, Michele, Brownell, Isaac, Lewis, Karl D, Lorch, Jochen H, Chin, Kevin, Mahnke, Lisa, von Heydebreck, Anja, Cuillerot, Jean-Marie, Nghiem, Paul
Publicat a Lancet Oncol (2016)

The Impact of Hashimoto Thyroiditis on Thyroid Nodule Cytology and Risk of Thyroid Cancer

per Silva de Morais, Nathalie, Stuart, Jessica, Guan, Haixia, Wang, Zhihong, Cibas, Edmund S, Frates, Mary C, Benson, Carol B, Cho, Nancy L, Nehs, Mathew A, Alexander, Caroline A, Marqusee, Ellen, Kim, Mathew I, Lorch, Jochen H, Barletta, Justine A, Angell, Trevor E, Alexander, Erik K
Publicat a J Endocr Soc (2019)

SUN-LB75 The Anti-Tumor Activity of the Selective Ret Inhibitor Selpercatinib (LOXO-292) in Medullary Thyroid Cancer Is Independent of the Specific RET Mutation

per Cabanillas, Maria E, Wirth, Lori J, Sherman, Eric J, Drilon, Alexander, Solomon, Benjamin, Robinson, Bruce G, Lorch, Jochen H, McCoach, Caroline, Patel, Jyoti, Leboulleux, Sophie, Worden, Francis, Owonikoko, Taofeek K, Brose, Marcia S, Taylor, Matthew H, Subbiah, Vivek, Rothenberg, S Michael, Huang, Xin, Zhu, Edward, French, Pearl P, Shah, Manisha H
Publicat a J Endocr Soc (2020)